Abstract: The present disclosure is drawn to the combination therapy of a C—C Chemokine Receptor 4 (CCR4) antagonist and one or more immune checkpoint inhibitors in the treatment of cancer.

Abstract: Disclosed is an antibody, functional fragment, and derivative thereof, which binds specifically to the OAcGD2 ganglioside, the antibody including i) a humanized light chain variable region (VL) polypeptide having the amino acid sequence SEQ id no 112; and ii) a humanized heavy chain variable region (VH) having the amino acid sequence SEQ id no 76; and its use in diagnostics and therapy.

Abstract: In some aspects, the invention relates to an antibody-drug conjugate, comprising an antibody; a linker; and an active agent. The antibody-drug conjugate may comprise a self-immolative group. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.

Abstract: Disclose herein are dosing regimens for targeted NaPi2b antibody-drug conjugates for treating cancer.

Abstract: Compounds according to formula II are useful as agonists of Toll-like receptor 7 (TLR7). Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.

Abstract: The present disclosure provides humanized antibodies and antibody-drug conjugates that specifically bind to human tissue factor, and which do not inhibit tissue factor mediated blood coagulation compared to a normal plasma control. Further described are methods of making and methods of using the disclosed humanized antibodies and antibody-drug conjugates in the treatment of cancer.

Abstract: The present disclosure provides biparatopic antibodies comprising polypeptides that bind to folate receptor alpha (FR?) compositions comprising such biparatopic antibodies. In a specific aspect, the biparatopic antibodies bind to FR? and modulate FR? activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering a biparatopic antibody that specifically binds to FR? and modulates FR? activity.

Abstract: The present invention provides antibodies that specifically bind to CD70 (Cluster of Differentiation 70). The invention further provides bispecific antibodies that bind to CD70 and another antigen (e.g., CD3). The invention further relates to antibody encoding nucleic acids, and methods of obtaining such antibodies (monospecific and bispecific). The invention further relates to therapeutic methods for use of these antibodies for the treatment of CD70-mediated pathologies, including cancer.

Abstract: The present invention provides a peptide having high binding affinity for PD-L1 protein and use thereof. The peptide has an amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 3 or SEQ ID NO: 4, or the peptide is a tandem or branched peptide with a single repeat or multiple repeats of SEQ ID NO: 1, SEQ ID NO: 3 and SEQ ID NO: 4 and has an amino acid sequence of SEQ ID NO: 5. The peptide can bind to human PD-L1 with high affinity, competitively block the affinity of PD-1/PD-L1 protein, block the negative regulatory tolerance pathway of human tumors, activate immunity and increase the lethality of T cells against tumor cells.

Abstract: This document relates to methods and materials involved in treating a mammal having, or at risk of developing, cytokine release syndrome (CRS). For example, a mammal having, or at risk of developing, CRS can be treated by administering one or more biguanides (e.g., metformin) to the mammal.

Abstract: The disclosure provides antigen binding proteins useful in the recognition of tumor cells and tumor specific delivery of drugs and therapies.

Abstract: The present disclosure relates to methods and compositions for treating cancer with a diaryl macrocycle in combination with at least one other cancer therapeutic, such as an EGFR inhibitor.

Abstract: Disclosed herein are uses of a mammalian target of rapamycin (mTOR) inhibitor and chloroquine or analogue thereof in the manufacture of a medicament for treating cancer patients who are not responsive to a hormone therapy and an immunotherapy. In particular, the medicament is used during the hormone therapy and the immunotherapy to sensitize the patients to the hormone therapy and the immunotherapy.

Abstract: The present invention provides a glycosylated CEA-specific single-chain antibody, and a chimeric antigen receptor (CAR) targeting a glycosylated CEA, which can be used in manufacture of an agent or a medicament for diagnosis or treatment of a tumor overexpressing glycosylated CEA.

Abstract: The present invention relates to an antigen-binding protein, or an antigen-binding fragment thereof which binding to CEACAM6, comprising (i) a heavy chain variable domain comprising a VHCDR1 having the amino acid sequence GNTFTSYVMH; a VHCDR2 having the amino acid sequence YINPYNDGTKYNEKFKG; and a VHCDR3 having the amino acid sequence STARATPYFYAMDY and (ii) a light chain variable domain comprising a VLCDR1 having the amino acid sequence KSSQSLLWSVNQNSYLS, a VLCDR2 having the amino acid sequence GASIRES, and a VLCDR3 having the amino acid sequence QHNHGSFLPYT. The present invention also relates to compositions comprising the antigen-binding protein, or antigen-binding fragment thereof, methods of use of the antigen-binding protein, or antigen-binding fragment thereof for cancer treatment, prevention or detection and a kit comprising the antigen-binding protein, or antigen-binding fragment thereof.

Abstract: Provided are methods involving combination therapy comprising administering to an individual in need thereof an antibody that preferentially depletes human B10 cells and an immune checkpoint inhibitor. Antibodies for use in the methods are also provided.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: The present disclosure relates to antibodies that specifically bind a novel epitope on the AxI protein. Also disclosed are methods for the production and use of the anti-Axl antibodies.

Abstract: [Problem] The present invention provides an antibody that binds to TMEM132A, an anticancer agent and a cancer test method. [Solution] An antibody that binds to TMEM132A.